Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $20,064.21 in Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 12,619 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total transaction of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares in the company, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Friday, January 3rd, Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ ABOS opened at $1.65 on Friday. Acumen Pharmaceuticals, Inc. has a 12 month low of $1.53 and a 12 month high of $5.09. The company has a market cap of $99.13 million, a P/E ratio of -1.20 and a beta of 0.02. The business’s 50 day moving average is $1.95 and its two-hundred day moving average is $2.46. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same period last year, the company earned ($0.24) EPS. On average, equities analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. FMR LLC increased its stake in Acumen Pharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 2,028,117 shares of the company’s stock valued at $5,030,000 after acquiring an additional 6,014 shares during the period. SG Americas Securities LLC grew its holdings in shares of Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock worth $44,000 after purchasing an additional 7,859 shares in the last quarter. American Century Companies Inc. increased its position in shares of Acumen Pharmaceuticals by 31.3% during the second quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after purchasing an additional 10,840 shares during the period. Barclays PLC raised its stake in shares of Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock valued at $154,000 after purchasing an additional 40,551 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Acumen Pharmaceuticals by 252.8% in the third quarter. JPMorgan Chase & Co. now owns 63,066 shares of the company’s stock worth $156,000 after purchasing an additional 45,189 shares during the period. Institutional investors and hedge funds own 71.01% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.